甲蓝可降低人类心血管脂肪组织中单胺氧化酶表达和氧化应激
Oana-Maria Aburel1,2, Laurențiu Brăescu2,3,4,5, Darius G Buriman1,2,3
1Chair of Pathophysiology, Department III, "Victor Babeş" University of Medicine and Pharmacy of Timișoara, E. Murgu Sq. No. 2, 300041, Timişoara, Romania.
Molecular and cellular biochemistry
|August 21, 2024
概括
甲蓝 (MB) 减少心血管脂肪组织中单胺氧化酶 (MAO) 表达和氧化应激. 这表明MB可能会减轻MAO-A.
科学领域:
- 心血管生物学 心血管生物学
- 脂肪组织的新陈代谢
- 线粒体功能的功能
背景情况:
- 心血管疾病,特别是心力衰竭,是致病的主要原因.
- 心脂肪组织 (EAT) 和周血管脂肪组织 (PVAT) 导致心脏代谢疾病.
- 单胺氧化酶 (MAO) 在心脏代谢病理中产生反应性氧物种 (ROS).
研究的目的:
- 研究甲蓝 (MB) 对MAO表达和EAT和PVAT中的氧化应激的影响.
- 为了确定人类心血管脂肪组织中占主导地位的MAO异型.
- 评估MB在缓解MAO介导氧化应激方面的潜力.
主要方法:
- 从心力衰竭患者中对EAT和PVAT进行试点研究 (n=25).
- 脂肪组织与MB (0.1μM/24小时) 的化.
- 评估MAO基因/蛋白质表达 (qPCS,免疫光) 和ROS产生 (共聚焦显微镜,光谱仪).
主要成果:
- 人类心血管脂肪组织表达MAO-A和MAO-B,其中MAO-A占主导地位.
- MB化显著降低了MAO表达和ROS产量.
- 血清激素的共同化增加了ROS,这种效应被MB部分逆转.
结论:
- 甲是EAT和PVAT中主要的甲异型,有助于局部氧化应激.
- 甲蓝有效地减轻MAO表达和氧化应激在这些组织.
- MB显示出作为治疗心脏代谢病理的治疗剂的潜力.
相关概念视频
Cholesterol: Significance and Regulation
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...


